One-stop Custom AAV Packaging Services
One-stop CDMO Services for GMP Manufacturing
Technology Platforms
π-Icosa AAV Serotype Screening Platform
Projects Delivery
Clients
GMP Facility
What Customers Are Saying About Us
Leading technology and global reputation
Decibel, Principal Scientist
“A lot of our programs internally have been having great results with the AAV vectors you all have been packaging. PackGene is rapidly becoming our go-to for AAV vectors! ”
Biogen Scientist
“I have spreaded the word of my satisfaction with your AAV vectors to many people in Biogen’s research labs and I hope we continue to be a regular customer in the future.”
Learn More About Us
NeuExcell’s NXL-004 Secures FDA Orphan Drug Designation for Glioma Treatment
On December 7, 2023, Beijing time, NeuExcell Therapeutics announced that its proprietary AAV gene therapy product, NXL-004, designed for treating malignant glioma, has been awarded Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). This...
PackGene Biotech Receives Exclusive C+ Round Investment from SDIC Fund, and Hosts a CGT Industry Salon to Discuss Global Strategies
December 1, 2023, PackGene Biotech, a frontrunner in gene therapy delivery, has successfully closed a landmark C+ funding round, securing over 100 million RMB exclusively from SDIC Fund Management Co., Ltd. This funding, a remarkable accomplishment in the current...
Tauopathy’s Role in Aβ Oligomer Formation: New Insights from Transgenic Primate Models on Alzheimer’s Pathogenesis
Tauopathy, characterized by protein tau and Aβ oligomer accumulation, is a significant aspect of Alzheimer's disease. The causal relationship between these accumulations and neurodegeneration remains unclear despite their links to various cognitive and movement...
Targeted Lysosomal Degradation of Mutant Huntingtin by Engineered Intrabody Peptide SM3
Huntington's disease (HD) is a devastating neurodegenerative condition caused by a mutation in the Huntingtin gene (HTT). This leads to the production of a mutant form of the huntingtin protein (mHTT) with an extended polyglutamine (polyQ) repeat, which has a...
Researchers Unveil a Novel Strategy for Protein Miniaturization in the CRISPR-Cas System
In a groundbreaking study published in Nature Communications, a team of researchers from China have introduced an innovative approach to protein miniaturization within the gene-editing realm of the CRISPR-Cas system. The CRISPR-Cas system is celebrated for its...
PackGene Biotech and Kudo Biotechnology Partner to Offer Customized mRNA Manufacturing Services
Collaboration provides end-to-end coverage of mRNA drug and vaccine development and manufacturing workflow HOUSTON, TX and NEEDHAM, MA – PackGene Biotech (PackGene) and Kudo Biotechnology (Kudo Bio) have partnered to provide high-quality, customized messenger RNA...
Zolgensma’s Success in SMA Treatment Advocates for AAV-based Gene Therapy and Promises a Bright Future for Genetic Disorders
At the 2023 Muscular Dystrophy Association Clinical and Scientific Conference, Novartis presented new data highlighting the continued efficacy and durability of its gene therapy treatment, Zolgensma, in treating spinal muscular atrophy (SMA). Zolgensma has been shown...
International Rare Disease Day | PackGene GMP plasmid is DMF registered, helping drug applications and shining lights on rare disease therapy!
February 28th is the 16th International Rare Disease Day with the theme of "Shine lights on your life" . Rare diseases, also known as "orphan diseases", have a low incidence rate and multiple disease types. Most of them are chronic, lifelong, severe, and...
Webinar: Treating Autosomal Recessive Deafness 9 with AAV1-hOTOF Gene Therapy (4/24/2024 10:00am EST/ 7:00am PST)
Abstract:Discover a groundbreaking advancement in treating Autosomal Recessive Deafness 9 (ARD9) with Dr. Yilai Shu, a pioneer in gene therapy for hearing loss. This webinar delves into the innovative AAV1-hOTOF gene therapy trial, offering new hope for individuals...
ASGCT (Maryland, May 7-11, 2024)
Abstract:Welcome to ASGCT 2024, the American Society of Gene and Cell Therapy's flagship conference. Esteemed researchers, clinicians, and industry leaders converge at this influential event to navigate the forefront of gene and cell therapy. In the vibrant atmosphere...
American Academy of Neurology (Colorado, Apri 13-18, 2024)
Abstract:The American Academy of Neurology Conference 2024 in Denver, a pivotal gathering for the brightest minds in neurology. This esteemed event brings together experts, researchers, clinicians, and innovators from around the globe to explore the forefront of...
Advanced Therapies Congress (London, Mar 19-20, 2024)
Abstract:The Advanced Therapies Congress convenes leaders in cell and gene therapy development across diverse sectors: pharma, biotech, startups, researchers, clinicians, academics, HTAs, payers, and regulators. In 2024, our new Gene Editing Track highlights CRISPR...
MDA (Florida, Mar 3-6, 2024)
Abstract:The Muscular Dystrophy Association (MDA) holds the top spot as the leading voluntary health organization in the United States, catering to individuals grappling with muscular dystrophy, ALS, and associated neuromuscular conditions. For over 70 years, MDA has...
Webinar: Overcoming Challenges in Preclinical NHP and Large Animal Studies for AAV-Based Gene Therapy through Improved AAV Purification and Quality Control Strategies
Abstract:Are you currently involved in the development of AAV-based gene therapy, specifically with non-human primates (NHP) or other large animals? Whether your focus is on constructing disease models or conducting pre-IND safety and toxicity studies, there are...
Webinar: Quality Delivery of mRNA – LNP with An Unbeatable Timeline
Abstract:Kudo Biotechnology is a global mRNA CDMO company headquartered in Singapore, providing world-class end-to-end cGMP manufacturing solutions for your mRNA needs. Kudo streamlines the manufacturing process of plasmid DNA, mRNA, lipid nanoparticle (LNP) and...
ESGCT 30th ANNUAL CONGRESS BRUSSELS
Time: 24-27 Oct 2023Address: Maison de la Poste, Bruxelles, Brussels, BelgiumContact: Irene Song (Sr. Director, Global Product) irene.song@packgene.comPoster P149:Generation of novel AAV serotype with enhanced infectivity, specificity, and lower toxicity via π-Icosa...
Ipsen and Skyhawk Therapeutics Announce Collaboration on RNA-Modulating Small Molecules for Rare Neurological Diseases
PARIS and BOSTON, April 22, 2024 – In a significant development in the biopharmaceutical industry, Ipsen and Skyhawk Therapeutics have entered into an exclusive global agreement to advance the discovery and development of novel small molecules that target RNA. These...
Lupus Research Alliance Announces Expanded FDA Partnership to Enhance Lupus Treatment Development
The Lupus Research Alliance (LRA), during the first anniversary meeting of the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), proudly announced an expanded partnership with the U.S. Food and Drug Administration (FDA). This new collaboration includes the...
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
Fully non-viral approach to genetic medicine employs differentiated gene delivery, gene editing and gene insertion technology Progressing two fully non-viral programs in rare disease with significant unmet patient need Virtual R&D Day featuring academic experts...
Africa CDC blasts Moderna after it halts plans to build vaccine plant in Kenya
The Africa CDC responded to Moderna’s plans to step back from building a mRNA vaccine manufacturing facility in Kenya, saying the move by the Spikevax maker only "perpetuates" the inadequate response to the COVID-19 pandemic on the continent. Last week, Moderna...
Voyager Therapeutics Advances Gene Therapy Candidate in Partnership with Neurocrine Biosciences
LEXINGTON, Mass., April 16, 2024-- Voyager Therapeutics, Inc. (Nasdaq: VYGR), today announced a significant milestone in its collaboration with Neurocrine Biosciences. The joint steering committee has selected a lead development candidate from the GBA1 gene therapy...
CureVac, MD Anderson Enter Strategic Cancer Vax Pact
CureVac N.V., a global biopharmaceutical company developing a new class of medicines based on messenger ribonucleic acid (mRNA), and The University of Texas MD Anderson Cancer Center entered a co-development and licensing agreement to develop novel mRNA-based cancer...
Mouse study finds small extracellular vesicles from young blood extend lifespan and restore physiological functions
New research presents a significant discovery: small extracellular vesicles (sEVs) from the blood of young mice possess the capacity to dramatically extend lifespan, rejuvenate whole-body physiology and reverse age-related degenerative changes in aged mice. The work...
NMDP BioTherapies Introduces Enhanced Cellular Materials for Allogeneic Cell Therapy Development
First of Its Kind Clinical-Grade Leukopak Now Facilitates Easier Regulatory Filing with Access to a DMF and Identification of Additional Characteristics Required to Qualify Cord Blood Units as Starting Material for Manufacture of Cell and Gene Therapies...
PackGene’s Newsletter
Receive the latest news and insights to your inbox.